 |
seribantumab |
|---|---|
| Trade Name | |
| Orphan Indication | Non-small cell lung cancer |
| USA Market Approval | USA |
| USA Designation Date | 2017-10-25 00:00:00 |
| Sponsor | Merrimack Pharmaceuticals, Inc.;1 Kendall Square, Suite B7201;Cambridge, Massachusetts, 02139 |
Related Access Program